Search
forLearn
5 / 801 resultslearn loca festival
learn taurine
learn Trifolium pratense
learn triticum vulgare
Research
5 / 94 resultsresearch Differential dependency of unmyelinated and A delta epidermal and upper dermal innervation on neurotrophins, trk receptors, and p75LNGFR.
Neurotrophins regulate nerve growth by balancing promotion and suppression.
research New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP3‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75NTRand TrkA) inex vivohuman male androgenetic scalp hair follicles
Caffeine may help reduce stress-induced hair loss.
research Optogenetically Controlled TrkA Activity Improves the Regenerative Capacity of Hair‐Follicle‐Derived Stem Cells to Differentiate into Neurons and Glia
Blue-light activation of TrkA improves hair-follicle stem cells' ability to become neurons and glial cells.
research Effects of the selective TrkA agonist gambogic amide on pigmentation and growth of human hair follicles in vitro
Gambogic Amide helps maintain hair color and promotes hair growth.
research Probing the Effects of Stress Mediators on the Human Hair Follicle
Stress-related substance P may lead to hair loss and negatively affect hair growth.
Community Join
5 / 1000+ resultscommunity What vehicle is being used in the breezula trial?
The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Will kintor show pyrilutamide phase 3 trials result this q
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.